Clinical Trial

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-09-21; most recent amendment 2023-12-29.
Status change: Not Yet Recruiting → Recruiting 2022-10-21
Trial Details
NCT Number NCT05553873
Lead Sponsor University of Milano Bicocca
Conditions Myeloproliferative Disease, Inflammatory Markers
Enrollment 500 participants
Start Date 2022-09-08
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-01-02